We serve Chemical Name:N-Ethyl-2-(1-Ethyl-2-Hydroxy-2-Nitrosohydrazino) Ethanamine Discontinued CAS:146724-89-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:N-Ethyl-2-(1-Ethyl-2-Hydroxy-2-Nitrosohydrazino) Ethanamine Discontinued
CAS.NO:146724-89-2
Synonyms:MFCD00674898;3-Ethyl-3-(ethylaminoethyl)-1-hydroxy-2-oxo-1-triazene;NOC-12
Molecular Formula:C6H16N4O2
Molecular Weight:176.21700
HS Code:2928000090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:264.6ºC at 760 mmHg
Density:1.15g/cm3
Index of Refraction:1.507
PSA:76.61000
Exact Mass:176.12700
LogP:1.09860
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like MFCD00674898 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,NOC-12 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,NOC-12 Use and application,MFCD00674898 technical grade,usp/ep/jp grade.
Related News: “It’s truly an important scientific issue and important public health issue and FDA is actively exploring all regulatory options for providing access to additional doses of authorized vaccines in situations where data suggests the benefits would outweigh the risks,” Fink said. 1,3,3-trimethyl-2-[5-(1,3,3-trimethylindol-1-ium-2-yl)penta-2,4-dienylidene]indole,chloride manufacturers Stevanato’s been out of start-up mode for a while: The firm doubled its net profit to $94 million in 2020 on $779 million in revenues, which were up 23% from 2019. That strong growth in sales helped place Sergio Stevanato, 79, Giovanni’s son and the company’s chairman emeritus, on Forbes’ World’s Billionaires list for the first time in 2021, with a net worth of $1.9 billion. (3R)-3,7-dimethyloct-6-enoic acid suppliers About eight months after originally teaming up on neuromuscular diseases, Takeda and PeptiDream have expanded the pact to include several central nervous system targets, while revealing the tie-up could be worth more than $3.5 billion. 1-(4,6-Dihydrothieno[3,4-b]thiophen-2-yl)-2-ethylhexan-1-one vendor & factory.
